The TGA's schedule of fees and charges for regulatory activities related to therapeutic goods will be adjusted, effective July 1, 2026.
The new fees will create financial implications for sponsors, particularly for those managing products subject to pharmacovigilance and RMP obligations. This can affect their budgeting and compliance strategies.
Sponsors must prepare for increased costs tied to the submission and maintenance of products on the ARTG which will impact their regulatory budget planning and compliance processes.
Regulatory Intelligence Lead
Review before 2026-07-01.
Adjustment of fees for various regulatory activities, including product evaluation and registration, which impacts sponsors maintaining products on the Australian Register of Therapeutic Goods (ARTG).
Financial implications for sponsors regarding the cost of regulatory maintenance and submissions, which includes products under pharmacovigilance monitoring and RMP obligations.
Sponsors must prepare for increased costs tied to the submission and maintenance of products on the ARTG which will impact their regulatory budget planning and compliance processes.
The TGA has outlined an updated schedule of fees and charges for applications and maintenance of therapeutic goods, becoming effective from July 1, 2026. This adjustment impacts sponsors maintaining products on the Australian Register of Therapeutic Goods (ARTG) significantly, as it alters the financial obligations associated with regulatory activities, including those under pharmacovigilance monitoring and Risk Management Plan (RMP) duties.
What changed: The TGA's schedule of fees and charges for regulatory activities related to therapeutic goods will be adjusted, effective July 1, 2026.
Why it matters: The new fees will create financial implications for sponsors, particularly for those managing products subject to pharmacovigilance and RMP obligations. This can affect their budgeting and compliance strategies.
Practical implication: Sponsors must prepare for increased costs tied to the submission and maintenance of products on the ARTG which will impact their regulatory budget planning and compliance processes.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
